Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary toxicity with mefloquine.

E Udry1, F Bailly, M Dusmet

  • 1Division de Pneumologie, Centre Hospitalier Universitaire Vaudois, Institut Pathologic, Lausanne, Switzerland.

The European Respiratory Journal
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and antimicrobial resistance of opportunistic pathogens associated with bovine respiratory disease isolated from nasopharyngeal swabs of veal calves in Switzerland.

Preventive veterinary medicine·2020
Same author

[Hepatitis C in a psychiatric setting: A forgotten reservoir?]

L'Encephale·2020
Same author

Associations between antimicrobial treatment modalities and antimicrobial susceptibility in Pasteurellaceae and E. coli isolated from veal calves under field conditions.

Veterinary microbiology·2019
Same author

[Transport of veal calves from birth farms to veal farms and calf management in Swiss dairy farms].

Schweizer Archiv fur Tierheilkunde·2019
Same author

Effects of management practices, animal transport and barn climate on animal health and antimicrobial use in Swiss veal calf operations.

Preventive veterinary medicine·2019
Same author

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

HIV medicine·2017
Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026
Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026
Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026
Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026
Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026
Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026
See all related articles

Mefloquine can cause acute lung injury and diffuse alveolar damage, even in patients without glucose-6-phosphate dehydrogenase deficiency. This rare side effect highlights the importance of monitoring patients after malaria treatment.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Mefloquine is a common antimalarial drug.
  • Acute lung injury (ALI) is a severe adverse reaction.
  • Previous reports suggested glucose-6-phosphate dehydrogenase (G6PD) deficiency as a risk factor for mefloquine-induced ALI.

Observation:

  • A case of acute lung injury developed rapidly after mefloquine administration for persistent P. falciparum malaria.
  • Microbiological investigations were negative, and lung biopsy revealed diffuse alveolar damage.
  • The patient recovered without specific treatment.

Findings:

  • This is the second reported case of mefloquine-induced acute lung injury and diffuse alveolar damage.
  • Unlike a previous case, the patient in this report had normal Glucose-6-phosphate dehydrogenase levels.

Related Experiment Videos

  • This suggests G6PD deficiency is not a necessary predisposing factor for mefloquine-induced ALI.

    • Implications:

    • Clinicians should be aware of the potential for mefloquine to cause acute lung injury.
    • Further research is needed to understand the mechanisms and risk factors for mefloquine-induced ALI.
    • This case expands the understanding of mefloquine's adverse effects beyond previously identified risk factors.